Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xoma ( (XOMA) ) has issued an update.
XOMA Royalty Corporation, a company involved in royalty monetization, entered into a share purchase agreement with LAVA Therapeutics N.V., a Dutch company, on August 3, 2025. On November 21, 2025, XOMA announced the expiration of the Subsequent Offering Period and the completion of the Post-Offer Reorganization, which resulted in LAVA shareholders receiving cash and contingent value rights for their shares, marking a significant step in XOMA’s acquisition strategy.
The most recent analyst rating on (XOMA) stock is a Hold with a $35.00 price target. To see the full list of analyst forecasts on Xoma stock, see the XOMA Stock Forecast page.
Spark’s Take on XOMA Stock
According to Spark, TipRanks’ AI Analyst, XOMA is a Neutral.
Xoma’s overall stock score is primarily influenced by its financial performance, which shows strong profitability but is offset by high leverage and cash flow concerns. Technical analysis indicates mixed signals, with bearish momentum prevailing. The valuation suggests the stock may be overvalued, further impacting the score.
To see Spark’s full report on XOMA stock, click here.
More about Xoma
Average Trading Volume: 52,791
Technical Sentiment Signal: Buy
Current Market Cap: $410.5M
For detailed information about XOMA stock, go to TipRanks’ Stock Analysis page.